International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer (T-REX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02938481|
Recruitment Status : Active, not recruiting
First Posted : October 19, 2016
Last Update Posted : April 5, 2019
|Condition or disease|
In colon canser, the incidence of metastasis in the pericolic lymph nodes (LNs) located along the bowel and marginal artery is high. The optimal extent of bowel resection is closely associated with how we define 'regional' pericolic LNs, which should be resected because of the risk of metastasis. However, there are no standardised criteria for 'regional' LNs in the pericolic area.
To establish a consensus for the extent of bowel resection and appropriate central LN dissection, international prospective stdies focusing on the distribution of metastatic LNs along the bowel and the primary feeding artery are conducted.
|Study Type :||Observational|
|Estimated Enrollment :||4000 participants|
|Official Title:||International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer|
|Actual Study Start Date :||January 22, 2015|
|Estimated Primary Completion Date :||January 2023|
|Estimated Study Completion Date :||January 2023|
- Distribution of metastatic LNs [ Time Frame: At the time of patient registry in ]
- Prognostic outcomes according to the length of bowel resection [ Time Frame: 3 years ]
- Prognostic outcomes according to the central radicality [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
- Resected surgical specimens to take photographs
- Lymph nodes retrieved from Resected surgical specimens to categorise
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02938481
|Study Director:||Kenichi Sugihara, M.D., Ph.D||Tokyo Medical and Dental University, Japan|